Bioactivity:

Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-_. Phase 3.

CAS nr:

649735-46-6

Purity:

98%

Molecular Weight:

370,38

SMILES:

C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C

Formula:

C19H19FN4O3

Pathway:

Tyrosine Kinase/Adaptors,Angiogenesis,Angiogenesis,Autophagy,Tyrosine Kinase/Adaptors,Angiogenesis,JAK/STAT signaling,Tyrosine Kinase/Adaptors

Target:

VEGFR,VEGFR,FGFR,Autophagy,FGFR,EGFR,EGFR,EGFR